2584 related articles for article (PubMed ID: 26829989)
1. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
[TBL] [Abstract][Full Text] [Related]
2. Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.
Berhie SH; Riley LE; Bryant AS
Am J Perinatol; 2019 Aug; 36(10):1066-1071. PubMed ID: 30508869
[TBL] [Abstract][Full Text] [Related]
3. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
Timofeev J; Singh J; Istwan N; Rhea D; Driggers RW
Am J Perinatol; 2014 Jan; 31(1):55-60. PubMed ID: 23456908
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
6. The interaction between maternal race/ethnicity and chronic hypertension on preterm birth.
Premkumar A; Henry DE; Moghadassi M; Nakagawa S; Norton ME
Am J Obstet Gynecol; 2016 Dec; 215(6):787.e1-787.e8. PubMed ID: 27555318
[TBL] [Abstract][Full Text] [Related]
7. Different levels of associations between medical co-morbidities and preterm birth outcomes among racial/ethnic women enrolled in Medicaid 2014-2015: retrospective analysis.
Lee H; Okunev I; Tranby E; Monopoli M
BMC Pregnancy Childbirth; 2020 Jan; 20(1):33. PubMed ID: 31931778
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
DeNoble AE; Wynn CE; Weaver KE; Wheeler SM; Swamy GK
Am J Perinatol; 2020 Feb; 37(3):264-270. PubMed ID: 30708392
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
10. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
11. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
[TBL] [Abstract][Full Text] [Related]
13. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
14. Racial/Ethnic Differences in Correlates of Spontaneous and Medically-Indicated Late Preterm Births among Adolescents.
Tabet M; Jakhar S; Williams CA; Rawat U; Hailegiorgis YD; Flick LH; Chang JJ
J Pediatr Adolesc Gynecol; 2017 Feb; 30(1):63-70. PubMed ID: 27543000
[TBL] [Abstract][Full Text] [Related]
15. Racial and ethnic disparities in birth outcomes and labour and delivery-related charges among women with intellectual and developmental disabilities.
Akobirshoev I; Mitra M; Parish SL; Moore Simas TA; Dembo R; Ncube CN
J Intellect Disabil Res; 2019 Apr; 63(4):313-326. PubMed ID: 30576027
[TBL] [Abstract][Full Text] [Related]
16. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
[TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Disparities in Diabetes Screening Between Asian Americans and Other Adults: BRFSS 2012-2014.
Tung EL; Baig AA; Huang ES; Laiteerapong N; Chua KP
J Gen Intern Med; 2017 Apr; 32(4):423-429. PubMed ID: 27848187
[TBL] [Abstract][Full Text] [Related]
18. Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.
Turitz AL; Bastek JA; Purisch SE; Elovitz MA; Levine LD
Am J Obstet Gynecol; 2016 Apr; 214(4):536.e1-536.e5. PubMed ID: 26519784
[TBL] [Abstract][Full Text] [Related]
19. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Heyborne KD; Allshouse AA; Carey JC
Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
[TBL] [Abstract][Full Text] [Related]
20. Birth hospital and racial and ethnic differences in severe maternal morbidity in the state of California.
Mujahid MS; Kan P; Leonard SA; Hailu EM; Wall-Wieler E; Abrams B; Main E; Profit J; Carmichael SL
Am J Obstet Gynecol; 2021 Feb; 224(2):219.e1-219.e15. PubMed ID: 32798461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
